Cytokine Measurements in Septic Shock
Authors: Charles A. Dinarello, Joseph G. Cannon
Journal: Annals of Internal Medicine (1993)

Editorials15 October 1993Cytokine Measurements in Septic ShockCharles A. Dinarello, MD and Joseph G. Cannon, PhDCharles A. Dinarello, MDTufts University and New England Medical Center, Boston, MA 02111. and Joseph G. Cannon, PhDTufts University and New England Medical Center, Boston, MA 02111.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-8-199310150-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The cytokines interleukin-1 (IL-1) and tumor necrosis factor (TNF) affect nearly every cell type by increasing the production of substances that promote local and systemic inflammatory processes. These include the up-regulation of the genes for cyclooxygenase and nitric oxide synthases, the release of platelet-activating factor, and the synthesis of endothelial adhesion molecules. Vasodilation, reduced tissue oxidation, and leukocyte-mediated necrosis are thought to contribute to organ failure and death in patients with septic shock. Although IL-1 and TNF are capable of inducing shock individually, of greater biological relevance is the synergistic action of these two cytokines.In animal models of disease, ...References1. Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol. 1987; 139:4129-34. Google Scholar2. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990; 348:550-2. Google Scholar3. Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest. 1992; 89:1551-7. Google Scholar4. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock. FASEB J. 1991; 5:338-43. Google Scholar5. Fanslow WC, Sims JE, Sassenfeld H, Morrissey PJ, Gillis S, Dower SK, et al. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science. 1990; 248:739-42. Google Scholar6. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ, Grau G, et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol. 1991; 21:2883-6. Google Scholar7. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990; 265:1531-6. Google Scholar8. Casey LC, Balk RA, Bone RC. Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993; 119:771-8. Google Scholar9. Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med. 1993; 21:318-27. Google Scholar10. Gershenwald JE, Fong YM, Fahey TJ 3d, Calvano SE, Chizzonite R, Kilian PL, et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA. 1990; 87:4966-70. Google Scholar11. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 and interleukin 6 appearance during lethal bacteremia. J Exp Med. 1989; 170:1627-33. Google Scholar12. Granowitz EV, Vannier E, Poutsiaka DD, Dinarello CA. 1992. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: II. Interleukin-1 receptor antagonist inhibits lipopolysaccharide-induced cytokine synthesis by human monocytes. Blood. 1992; 79:2364-9. Google Scholar13. Fisher CJ Jr, Dhainaut JF, Pribble J, Knaus W, Catalano MA. A study evaluating the efficacy of human recombinant interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: preliminary results from a Phase III multicenter trial (Abstract). 13th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium. New York: Springer-Verlag. Google Scholar14. Cannon JG, van der Meer JW, Kwiatkowski D, Endres S, Lonnemann G, Burke JF, et al. Interleukin-1 in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res. 1988; 7:457-67. Google Scholar15. Wogensen L, Jensen M, Svensson P, Worsaae H, Welinder B, Nerup J. Pancreatic -cell function and interleukin-1b in plasma during the acute phase response in patients with major burn injuries. Eur J Immunol. 1993; (In press). Google Scholar16. Cannon JG, Nerad JL, Poutsiaka DD, Dinarello CA. Measuring circulating cytokines. J Appl Physiol. 1993; (In press). Google Scholar17. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JW, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis. 1990; 161:79-84. Google Scholar18. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production of monocytes during sepsis. J Clin Invest. 1991; 88:1747-54. Google Scholar19. Dinarello CA. ELISA kits based on monoclonal antibodies do not measure total IL-1 synthesis. J Immunol Methods. 1992; 148:255-9. Google Scholar20. van der Meer JW, Barza M, Wolff SM, Dinarello CA. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci USA. 1988; 85: 1620-3. Google Scholar Author, Article, and Disclosure InformationAffiliations: Tufts University and New England Medical Center, Boston, MA 02111.Corresponding Author: Charles A. Dinarello, MD, Division of Geographic Medicine and Infectious Diseases, New England Medical Center Hospitals, 750 Washington Street, Box 68, Boston, MA 02111.Grant Support: In part by NIH grants AI15614, AI33414, and AR39595. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPlasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome Larry C. Casey , Robert A. Balk , and Roger C. Bone Metrics Cited byDevelopment of a Gold Nanoparticle-Based Colorimetric Sensor for Water for Injection At-Line Impurity TestingEndotoxin removal from human-like collagen by allantoinMortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*What is passing through toll gate 4: Lipids or infection?Can Tumor Necrosis Factor- α and Interleukin-6 Be Used as Prognostic Markers of Infection following Ureteroscopic Lithotripsy?Understanding organ dysfunction in hemophagocytic lymphohistiocytosisCardiac Function and Circulating Cytokines Following Endotoxin Exposure in Neonatal MiceRituximab-associated acute thrombocytopenia: An under-diagnosed phenomenonIL-1-dependent, IL-1R1-independent resistance to gastrointestinal nematodesβ-BLOCKERS IN SEPSISUnderstanding organ dysfunction in hemophagocytic lymphohistiocytosisUnderstanding organ dysfunction in hemophagocytic lymphohistiocytosisSystemic Expression of Cytokine Production in Patients with Severe Pneumococcal Pneumonia: Effects of Treatment with a β-Lactam versus a FluoroquinoloneInactivation of bacteria inoculated inside urinary stone-phantoms using intracorporeal lithotriptersDaptomycin Does Not Exert Immunomodulatory Effects in an Experimental Endotoxin Model of Human Whole BloodFever as a Cause of Hypophosphatemia in Patients with MalariaInterleukin-1alpha, interleukin-6 and tumor necrosis factor-alpha levels in children with sepsis and meningitisEndotoxin: The uninvited guestEvaluation of endotoxin release and cytokine production induced by antibiotics in patients with Gram-negative nosocomial pneumoniaA pilot study of pentoxifylline for the treatment of primary sclerosing cholangitisMeasurement of Soluble and Membrane‐Bound Interleukin 1 Using a Fibroblast BioassayRAPID DIAGNOSTIC METHODS IN THE DETECTION OF SEPSISPossibilities and problems of cytokine measurementsQuantification of cytokine mRNA in peripheral blood mononuclear cells using branched DNA (bDNA) technologyTumor necrosis factor in the heartPrevalence of Hypophosphatemia in Sepsis and Infection: The Role of CytokinesPilot Study of Cytokines in Emergency Department Patients with Systemic Inflammatory Response SyndromeUtilization of a chromogenic Limulus amebocyte lysate blood assay in a multi-center study of sepsisUse and Application of Cytokines and Growth Factors in Laboratory Diagnostic ProceduresRole of Cytokines in SepsisThe autonomic and neurohumoral response to critical illnessElevated interleukin-1β in the circulation of patients with essential hypertension before any drug therapy: a pilot studyActivation of the contact and fibrinolytic systems after intravenous administration of endotoxin to normal human volunteers: correlation with the cytokine profilePost hoc analyses in sepsis trialsUse of Predicted Risk of Mortality to evaluate the efficacy of anticytokine therapy in sepsisPlasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: Results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemiaVariable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standardsGlycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsisHigh levels of interleukin 10 in serum are associated with fatality in meningococcal diseaseDetection of cytoplasmic IL-1β in peripheral blood mononuclear cells from intensive care unit (ICU) patientsSepsis and septic shockEvidence for Inflammation as a Cause of Hypocholesterolemia in Older PeopleThe Interplay of Pro-Inflammatory Cytokines and Anti-Inflammatory Mediators during Severe InfectionProinflammatory Cytokines and the Host Response to CancerMeasurement of Inflammatory Mediators in Clinical SepsisThe pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis.A Retrospective Analysis of the Effect of Indomethacin on Adverse Reactions to Orthoclone OKT3 in the Therapy of Acute Renal Allograft RejectionCytokine Markers of the Human Response to SepsisKinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections 15 October 1993Volume 119, Issue 8Page: 853-854KeywordsAttentionBioassays and physiological analysisBlood plasmaCytokinesEndotoxinsEnzyme linked immunosorbent assayMortalityProteinsShockTumor necrosis factor Issue Published: 15 October 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...